Memantine (Ebixa) in the later stages of dementia.
Memantine is the first agent licensed for the treatment of moderate to severe Alzheimer's disease. It is an N-methyl D-aspartate (NMDA) receptor antagonist which reduces glutamatergic excitotoxicity. Benefits are seen in cognitive, functional and global measures in both outpatients and nursing home residents. Prospective health economic benefits have been reported.
Findlay
David J
DJ
Department of Old Age Psychiatry, Royal Dundee Liff Hospital, Dundee DD2 5NF.
Connelly
Peter J
PJ
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D015140:Dementia, Vascular / Q000188:drug therapy; D006801:Humans; D008559:Memantine / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D008559:Memantine